KTRAKintara Therapeutics, Inc.

Nasdaq kintara.com


$ 0.17 $ 0.00 (2.16 %)    

Monday, 16-Sep-2024 09:38:00 EDT
QQQ $ 471.58 $ -1.48 (-0.31 %)
DIA $ 416.29 $ 1.35 (0.33 %)
SPY $ 561.14 $ -0.33 (-0.06 %)
TLT $ 100.97 $ 0.35 (0.34 %)
GLD $ 238.41 $ -0.19 (-0.08 %)
$ 0.1664
$ 0.17
$ 0.17 x 1,200
-- x --
$ 0.17 - $ 0.17
$ 0.08 - $ 4.59
1,417,351
na
278,771
$ 1.09
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 02-14-2024 12-31-2023 10-Q
3 11-13-2023 09-30-2023 10-Q
4 09-18-2023 06-30-2023 10-K
5 05-11-2023 03-31-2023 10-Q
6 02-14-2023 12-31-2022 10-Q
7 11-09-2022 09-30-2022 10-Q
8 09-27-2022 06-30-2022 10-K
9 05-13-2022 03-31-2022 10-Q
10 02-11-2022 12-31-2021 10-Q
11 11-15-2021 09-30-2021 10-Q
12 09-28-2021 06-30-2021 10-K
13 05-13-2021 03-31-2021 10-Q
14 02-12-2021 12-31-2020 10-Q
15 11-12-2020 09-30-2020 10-Q
16 09-18-2020 06-30-2020 10-K
17 05-13-2020 03-31-2020 10-Q
18 02-13-2020 12-31-2019 10-Q
19 11-13-2019 09-30-2019 10-Q
20 09-09-2019 06-30-2019 10-K
21 05-14-2019 03-31-2019 10-Q
22 02-11-2019 12-31-2018 10-Q
23 11-13-2018 09-30-2018 10-Q
24 09-24-2018 06-30-2018 10-K
25 05-15-2018 03-31-2018 10-Q
26 02-14-2018 12-31-2017 10-Q
27 11-09-2017 09-30-2017 10-Q
28 09-27-2017 06-30-2017 10-K
29 05-12-2017 03-31-2017 10-Q
30 02-10-2017 12-31-2016 10-Q
31 11-10-2016 09-30-2016 10-Q
32 09-13-2016 06-30-2016 10-K
33 05-12-2016 03-31-2016 10-Q
34 02-12-2016 12-31-2015 10-Q
35 11-16-2015 09-30-2015 10-Q
36 09-03-2015 06-30-2015 10-K
37 05-15-2015 03-31-2015 10-Q
38 02-12-2015 12-31-2014 10-Q
39 11-07-2014 09-30-2014 10-Q
40 05-15-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 kintara-therapeutics-provides-update-on-rem-001-clinical-study-has-enrolled-4-of-the-10-patients-needed-to-reach-the-minimum-patient-enrollment-to-assess-safety-and-appropriate-phase-3-dose-with-several-other-patients-identified-as-study-candidates-at-kintaras-clinical-sites-no-treatment-related-safety-issues-have-been-identified-to-date-and-assessment-of-the-appropriate-phase-3-dose-is-ongoing

REM-001 Clinical Study UpdateAs of September 10, 2024, the REM-001 study in patients with cutaneous metastatic breast cancer (C...

 kintara-therapeutics-to-hold-special-meeting-for-completion-of-proposed-merger-with-tuhura-biosciences

Stockholders must vote by 11:59 p.m., Eastern Time, on September 19, 2024, for their vote to count

Core News & Articles

KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel t...

 tuhura-biosciences-and-kintara-therapeutics-announce-phase-1b-trial-of-ifx-20-in-checkpoint-inhibitor-resistant-advanced-merkel-cell-carcinoma-and-cutaneous-squamous-cell-carcinoma-results

TuHURA's lead candidate, IFx-2.0, was safe and well tolerated at once weekly dosing for 3 weeksEighty percent (80%) of ICI ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION